Exicure board shrinks from 5 to 4; two directors resign; new director appointed; audit committee non-compliant

EXICURE, INC.

James Sulat and Bali Muralidhar resigned from the Board effective December 30, 2022.
Board size decreased from five to four directors.
Jiyoung Hwang appointed to Board as lead purchaser designee from CBI USA.
Audit Committee now has only two independent directors, breaching Nasdaq Listing Rule 5605(c)(2)(A).
Company expects to regain compliance within one-year cure period or next annual meeting.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jiyoung Hwang

Lead Purchaser Board Designee

XCUR · EXICURE, INC.

Effective: 2022-12-30
Filed: December 30, 2022, 6:59 PM ET

Pursuant to the May 2022 Securities Purchase Agreement, the Board appointed Jiyoung Hwang to the Board as the Lead Purchaser Board Designee (as defined in the May 2022 Securities Purchase Agreement), effective December 30, 2022.

Departed

Bali Muralidhar

Director

XCUR · EXICURE, INC.

Effective: 2022-12-30
Filed: December 30, 2022, 6:59 PM ET

Effective December 30, 2022 (the “Resignation Date”), James Sulat and Bali Muralidhar, M.D., Ph.D. each resigned from the Board of Directors (the “Board”) of Exicure, Inc. (the “Company”).

Departed

James Sulat

Director

XCUR · EXICURE, INC.

Effective: 2022-12-30
Filed: December 30, 2022, 6:59 PM ET

Effective December 30, 2022 (the “Resignation Date”), James Sulat and Bali Muralidhar, M.D., Ph.D. each resigned from the Board of Directors (the “Board”) of Exicure, Inc. (the “Company”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jiyoung Hwang was appointed as Lead Purchaser Board Designee at EXICURE, INC..

Action: appointed
Role: Lead Purchaser Board Designee

Exact text from the filing

Pursuant to the May 2022 Securities Purchase Agreement, the Board appointed Jiyoung Hwang to the Board as the Lead Purchaser Board Designee (as defined in the May 2022 Securities Purchase Agreement), effective December 30, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Bali Muralidhar resigned as Director at EXICURE, INC..

Action: resigned
Role: Director

Exact text from the filing

Effective December 30, 2022 (the “Resignation Date”), James Sulat and Bali Muralidhar, M.D., Ph.D. each resigned from the Board of Directors (the “Board”) of Exicure, Inc. (the “Company”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

James Sulat resigned as Director at EXICURE, INC..

Action: resigned
Role: Director

Exact text from the filing

Effective December 30, 2022 (the “Resignation Date”), James Sulat and Bali Muralidhar, M.D., Ph.D. each resigned from the Board of Directors (the “Board”) of Exicure, Inc. (the “Company”).

View on SEC.gov

EXICURE, INC. filing history →

Source: SEC EDGAR

accession 0001698530-22-000103

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.